{"text_format":"1","workbook":"xlsx","n_sheets":1,"sheets":["Q4-2021"],"not_rendered":{"charts":0,"images":0,"macros":1,"external_links":0,"defined_names":2,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900"}

{"sheet":"Q4-2021","index":0,"n_rows":145,"n_cols":9,"rows_kept":145,"cut":false,"hidden":false,"merged":[]}
["Therapeutic area","Project ","Phase ","NCT number ","Title","Conditions ","Enrollment ","Sudy Design","Dates"]
["I&I","Dupixent (anti-IL4/IL13 mAb) ","\nPhase 3\n","NCT04456673","Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation","• Chronic Obstructive Pulmonary Disease",924,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: July 1, 2023\nStudy Completion: October 20, 2023"]
["I&I","Dupixent (anti-IL4/IL13 mAb) ","\n• Phase 2\n• Phase 3\n","NCT04206553","A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid","• Bullous Pemphigoid",98,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: February 27, 2023\nStudy Completion: September 15, 2023"]
["I&I","Dupixent (anti-IL4/IL13 mAb) ","\nPhase 3\n","NCT04202679","Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)","• Neurodermatitis",160,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: August 30, 2021\nStudy Completion: November 22, 2021"]
["I&I","Dupixent (anti-IL4/IL13 mAb) ","\nPhase 3\n","NCT04183335","Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those\nTherapies Are Not Advisable (LIBERTY-PN PRIME)","• Neurodermatitis",151,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: November 12, 2021\nStudy Completion: July 21, 2022"]
["I&I","Dupixent (anti-IL4/IL13 mAb) ","\nPhase 3\n","NCT04180488","Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab","• Chronic Spontaneous Urticaria",246,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: April 2022\nStudy Completion: March 18, 2024"]
["I&I","Dupixent (anti-IL4/IL13 mAb) ","\nPhase 3\n","NCT03930732","Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation","• Chronic Obstructive Pulmonary Disease",924,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: February 1, 2023\nStudy Completion: May 22, 2023"]
["I&I","Dupixent (anti-IL4/IL13 mAb) ","\nPhase 2\n","NCT03682770","Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)","• Peanut Allergy",149,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: October 16, 2020\nStudy Completion: July 23, 2021"]
["I&I","Dupixent (anti-IL4/IL13 mAb) ","\nPhase 3\n","NCT03633617","Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)","• Eosinophilic Esophagitis",321,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: September 9, 2021\nStudy Completion: July 1, 2022"]
["I&I","Dupixent (anti-IL4/IL13 mAb) ","\nPhase 3\n","NCT03560466","Assessment of the Safety and Efficacy of Dupilumab in Children With Asthma (Liberty Asthma Excursion)","• Asthma",365,"\n \n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: December 26, 2023\nStudy Completion: December 26, 2023"]
["I&I","Dupixent (anti-IL4/IL13 mAb) ","\nPhase 3\n","NCT02612454","Study to Assess the Long-term Safety of Dupilumab Administered in Participants #6 Months to <18 Years of Age With Atopic Dermatitis (AD)","• Atopic Dermatitis",800,"\n \n• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: November 3, 2026\nStudy Completion: November 3, 2026"]
["I&I","itepekimab (anti-IL33 mAb)","\nPhase 3\n","NCT04751487","Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/ Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) (AERIFY-2)","• Chronic Obstructive Pulmonary Disease",1170,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: February 2024\nStudy Completion: July 2024"]
["I&I","itepekimab (anti-IL33 mAb)","\nPhase 3\n","NCT04701983","Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/ Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)","• Chronic Obstructive Pulmonary Disease",930,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: December 2023\nStudy Completion: May 2024"]
["I&I","Dupixent (anti-IL4/IL13 mAb) ","\nPhase 3\n","NCT04684524","Dupilumab in Allergic Fungal Rhinosinusitis (AFRS)","• Allergic Fungal Rhinosinusitis",120,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: December 30, 2022\nStudy Completion: November 21, 2023"]
["I&I","Dupixent (anti-IL4/IL13 mAb) ","\nPhase 3\n","NCT04681729","Dupilumab for the Treatment of Chronic Inducible Cold Urticaria in Patients Who Remain Symptomatic Despite the Use of H1-antihistamine (LIBERTY-CINDU CUrIADS)","• Cold Urticaria",78,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: July 2022\nStudy Completion: November 2022"]
["I&I","Dupixent (anti-IL4/IL13 mAb) ","\nPhase 3\n","NCT04678856","Dupilumab in CRSsNP (Liberty CRSsNP ORION)","• Chronicrhinosinusitis Without Nasalpolyps\n• Sinusitis\n• Chronic Sinusitis\n• Sinus Disorder\n• Respiratory Disorder",240,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: July 31, 2023\nStudy Completion: May 30, 2024"]
["I&I","SAR441344 (anti-CD40L mAb)","\nPhase 2\n","NCT04572841","Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Primary Sjögren's Syndrome (pSjS)","• Sjögren's Syndrome",88,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: August 2022\nStudy Completion: October 2022"]
["I&I","rilzabrutinib (BTK inhibitor)","\nPhase 2\n","NCT04520451","Open Label Two-Arm Study to Evaluate Rilzabrutinib (PRN1008) in IgG4-Related Disease Patients","• IgG4-Related Disease",25,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: February 1, 2023\nStudy Completion: December 5, 2023"]
["I&I","Dupixent (anti-IL4/IL13 mAb) ","\nPhase 3\n","NCT04442269","A Study to Evaluate the Efficacy and Safety of Dupilumab in Participants With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED)","• Allergic Bronchopulmonary Aspergillosis",170,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: September 7, 2023\nStudy Completion: October 23, 2023"]
["I&I","Kevzara (anti-IL6 mAb) ","\nPhase 2\n","NCT02991469","A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)","• Juvenile Idiopathic Arthritis",72,"\n \n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: January 2023\nStudy Completion: April 2027"]
["I&I","Kevzara (anti-IL6 mAb) ","\nPhase 2\n","NCT02776735","An Open-label, Ascending, Repeated Dose- finding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA)","• Juvenile Idiopathic Arthritis",100,"\n \n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: March 31, 2022\nStudy Completion: February 6, 2024"]
["I&I","Amlitelimab (anti-OX40L mAb)","\nPhase 2\n","NCT05131477","Study Testing Response Effect of KY1005 Against Moderate to Severe Atopic Dermatitis The STREAM-AD Study","• Eczema",350,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: June 12, 2023\nStudy Completion: May 20, 2024"]
["I&I","SAR441344 (anti-CD40L mAb)","\nPhase 2\n","NCT05039840","Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus","• Systemic Lupus Erythematosus",116,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: June 2023\nStudy Completion: September 2023"]
["I&I","rilzabrutinib (BTK inhibitor)","\nPhase 2\n","NCT05018806","Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis","• Atopic Dermatitis",70,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: April 2023\nStudy Completion: April 2023"]
["I&I","SAR444727 (BTK inhibitor - topical)","\nPhase 2\n","NCT04992546","Phase 2a Study of the Safety, Tolerability, and Pharmacokinetics of Topically Administered PRN473 (SAR444727) in Patients With Mild to Moderate Atopic Dermatitis","• Atopic Dermatitis",40,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: August 2022\nStudy Completion: August 2022"]
["I&I","SAR443122 (RIPK1 inhibitor)","\nPhase 2\n","NCT04781816","Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus Erythematosus","• Cutaneous Lupus Erythematosus",88,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: November 23, 2022\nStudy Completion: December 26, 2022"]
["I&I","SAR444656 (IRAK4 degrader)","\nPhase 1\n","NCT04772885","A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)","• Healthy Volunteer\n• Atopic Dermatitis\n• Hidradenitis Suppurativa",124,"\n \n• Allocation: Randomized\n• Intervention Model: Sequential Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: February 1, 2022\nStudy Completion: February 1, 2022"]
["I&I","Amlitelimab (anti-OX40L mAb)","\nPhase 2\n","NCT03754309","A Study of KY1005 in Patients With Moderate to Severe Atopic Dermatitis","• Dermatitis, Atopic",89,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Triple (Participant, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: May 12, 2020\nStudy Completion: October 8, 2020"]
["Oncology","Sarclisa (anti-CD38 mAb)","\nPhase 1\n","NCT04045795","Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)","• Multiple Myeloma",46,"\n \n• Allocation: Randomized\n• Intervention Model: Sequential Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: January 2023\nStudy Completion: November 2023"]
["Oncology","Sarclisa (anti-CD38 mAb)","\nPhase 1\n","NCT03733717","Evaluation of Pharmacokinetics, Safety, and Preliminary Efficacy of Isatuximab in Chinese Patients With Relapsed and/or Refractory Multiple Myeloma","• Multiple Myeloma",25,"\n \n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: September 6, 2020\nStudy Completion: May 2, 2022"]
["Oncology","Sarclisa (anti-CD38 mAb)","\nPhase 3\n","NCT03617731","Trial on the Effect of Isatuximab to Lenaliodomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)","• Multiple Myeloma",662,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: May 2025\nStudy Completion: December 2025"]
["Oncology","Sarclisa (anti-CD38 mAb)","\nPhase 3\n","NCT03319667","Clinical Benefit of SAR650984, Bortezomib, Lenalidomide and Dexamethasone Combination in NDMM Patients Not Eligible for Transplant","• Plasma Cell Myeloma",475,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Single (Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: December 2022\nStudy Completion: April 15, 2025"]
["Oncology","Sarclisa (anti-CD38 mAb)","\nPhase 3\n","NCT02990338","Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients","• Plasma Cell Myeloma",307,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: November 22, 2018\nStudy Completion: September 30, 2022"]
["Oncology","Sarclisa (anti-CD38 mAb)","\n• Phase 1\n• Phase 2\n","NCT02812706","Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients","• Multiple Myeloma",32,"\n \n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: July 31, 2018\nStudy Completion: October 11, 2022"]
["Oncology","Sarclisa (anti-CD38 mAb)","\nPhase 1\n","NCT02514668","A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma","• Plasma Cell Myeloma",55,"\n \n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: December 30, 2021\nStudy Completion: December 30, 2021"]
["Oncology","Sarclisa (anti-CD38 mAb)","\nPhase 1\n","NCT02513186","Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation","• Plasma Cell Myeloma",90,"\n \n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: July 2026\nStudy Completion: July 2026"]
["Oncology","Sarclisa (anti-CD38 mAb)","\nPhase 1\n","NCT01749969","SAR650984 (Isatuximab), Lenalidomide, and Dexamethasone in Combination in RRMM Patients","• Plasma Cell Myeloma",60,"\n \n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: June 30, 2022\nStudy Completion: June 30, 2022"]
["Oncology","Sarclisa (anti-CD38 mAb)","\n• Phase 1\n• Phase 2\n","NCT01084252","Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies","• Hematological Malignancy",351,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: December 21, 2018\nStudy Completion: December 2021"]
["Oncology","Sarclisa (anti-CD38 mAb)","\nPhase 3\n","NCT04270409","Isatuximab in Combination With Lenalidomide and Dexamethasone in High- risk Smoldering Multiple Myeloma","• Plasma Cell Myeloma",323,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Single (Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: June 2028\nStudy Completion: October 2033"]
["Oncology","Libtayo (anti-PD-1 mAb)","\nPhase 2\n","NCT04154943","Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma","• Cutaneous Squamous Cell Carcinoma",80,"\n \n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: December 2, 2021\nStudy Completion: September 4, 2025"]
["Oncology","Libtayo (anti-PD-1 mAb)","\nPhase 3\n","NCT03969004","Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma","• Cutaneous Squamous Cell Carcinoma",412,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: December 19, 2025\nStudy Completion: February 28, 2027"]
["Oncology","Sarclisa (anti-CD38 mAb)","\nPhase 2\n","NCT03860844","Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia","• Acute Lymphoblastic Leukemia\n• Acute Myeloid Leukemia",96,"\n \n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: August 31, 2023\nStudy Completion: August 31, 2023"]
["Oncology","Sarclisa (anti-CD38 mAb)","\n• Phase 1\n• Phase 2\n","NCT03769181","A Study of Isatuximab-based Therapy in Participants With Lymphoma","• Lymphoma",130,"\n \n• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: February 15, 2021\nStudy Completion: October 24, 2022"]
["Oncology","Sarclisa (anti-CD38 mAb)","\n• Phase 1\n• Phase 2\n","NCT03637764","Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies","• Neoplasm",350,"\n \n• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: May 2022\nStudy Completion: May 2022"]
["Oncology","Sarclisa (anti-CD38 mAb)","\nPhase 3\n","NCT03275285","Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients","• Plasma Cell Myeloma",302,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Single (Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: March 1, 2022\nStudy Completion: February 7, 2023"]
["Oncology","Libtayo (anti-PD-1 mAb)","\nPhase 1\n","NCT03233139","Safety and Pharmacokinetics of REGN2810 (Cemiplimab) (Anti-PD-1) in Japanese Patients With Advanced Malignancies","• Advanced Malignancies",117,"\n \n• Allocation: Non-Randomized\n• Intervention Model: Sequential Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: May 24, 2026\nStudy Completion: May 24, 2026"]
["Oncology","Libtayo (anti-PD-1 mAb)","\nPhase 3\n","NCT03088540","Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)","• Carcinoma#Non-Small-Cell Lung\n• Lung Carcinomas, Non- Small-Cell\n• Non-small-cell Lung Carcinoma\n• Nonsmall Cell Lung Cancer",712,"\n \n• Allocation: Randomized\n• Intervention Model: Crossover Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: November 1, 2022\nStudy Completion: November 1, 2022"]
["Oncology","Libtayo (anti-PD-1 mAb)","\nPhase 2\n","NCT02760498","Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma","• Advanced Cutaneous Squamous Cell Carcinoma",433,"\n \n• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: October 20, 2025\nStudy Completion: December 1, 2025"]
["Oncology","tusamitamab ravtansine (anti-CEACAM5 ADC)","\nPhase 2\n","NCT04524689","Tusamitamab Ravtansine (SAR408701)  in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701)  in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC (CARMEN-LC05)","• Non-squamous Non-small- cell Lung Cancer (NSQ NSCLC)",96,"\n \n• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: April 2022\nStudy Completion: March 2024"]
["Oncology","tusamitamab ravtansine (anti-CEACAM5 ADC)","\nPhase 2\n","NCT04394624","SAR408701 in Combination With Ramucirumab in Pre-treated Patients With Non Squamous Non-small Cell Lung Cancer (NSQ NSCLC)","• Non-small Cell Lung Cancer Metastatic",36,"\n \n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: April 21, 2022\nStudy Completion: October 21, 2022"]
["Oncology","tusamitamab ravtansine (anti-CEACAM5 ADC)","\nPhase 3\n","NCT04154956","SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non- small Cell Lung Cancer Patients","• Non-small Cell Lung Cancer Metastatic",554,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: April 4, 2022\nStudy Completion: March 18, 2024"]
["Oncology","amcenestrant (SERD)","\nPhase 1\n","NCT03816839","Evaluation of Orally Administered Amcenestrant (SAR439859) in Japanese Postmenopausal Patients With Advanced Breast Cancer","• Breast Cancer",10,"\n \n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: October 27, 2020\nStudy Completion: May 31, 2022"]
["Oncology","Libtayo (anti-PD-1 mAb)","\nPhase 2\n","NCT03430063","A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer","• Advanced Non-Small Cell Lung Carcinoma",28,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: October 27, 2021\nStudy Completion: October 27, 2021"]
["Oncology","Libtayo (anti-PD-1 mAb)","\nPhase 3\n","NCT03409614","Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer","• Non-small Cell Lung Cancer",790,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: May 1, 2023\nStudy Completion: May 1, 2023"]
["Oncology","tusamitamab ravtansine (anti-CEACAM5 ADC)","\nPhase 1\n","NCT03324113","Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors","• Neoplasm Malignant",63,"\n \n• Allocation: N/A\n• Intervention Model: Sequential Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: August 2022\nStudy Completion: October 2022"]
["Oncology","amcenestrant (SERD)","\n• Phase 1\n• Phase 2\n","NCT03284957","Phase 1 / 2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer","• Breast Cancer",251,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: January 2024\nStudy Completion: January 2024"]
["Oncology","Libtayo (anti-PD-1 mAb)","\nPhase 3\n","NCT03257267","Study of Cemiplimab in Adults With Cervical Cancer","• Squamous Cell Carcinoma (SCC)\n• Recurrent or Metastatic, Platinum-refractory Cervical Cancer",608,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: March 15, 2021\nStudy Completion: July 9, 2023"]
["Oncology","tusamitamab ravtansine (anti-CEACAM5 ADC)","\n• Phase 1\n• Phase 2\n","NCT02187848","Evaluation of SAR408701 in Patients With Advanced Solid Tumors","• Neoplasm Malignant",263,"\n \n• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: March 31, 2022\nStudy Completion: March 31, 2022"]
["Oncology","Sarclisa (anti-CD38 mAb)","\nPhase 3\n","NCT04751877","Study of Isatuximab+Lenalidomide\n+Dexamethasone With/Without Bortezomib in de Novo Non Frail NTE Multiple Myeloma Elderly Patients","• Multiple Myeloma\n• Myeloma",270,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: April 2, 2024\nStudy Completion: August 17, 2026"]
["Oncology","Sarclisa (anti-CD38 mAb)","\n• Phase 1\n• Phase 2\n","NCT04643002","Isatuximab in Combination With Novel Agents in RRMM - Master Protocol","• Plasma Cell Myeloma Refractory",117,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: February 11, 2026\nStudy Completion: February 11, 2026"]
["Oncology","amcenestrant (SERD)","\nPhase 3\n","NCT04478266","Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer","• Breast Cancer",1068,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: January 2024\nStudy Completion: June 15, 2027"]
["Oncology","SAR442720 (SHP2 inhibitor)","\nPhase 1\n","NCT04418661","Safety and Efficacy Study of SAR442720 in Combination With Pembrolizumab in Advanced Malignancies","• Metastatic Neoplasm",88,"\n \n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: July 15, 2025\nStudy Completion: July 15, 2025"]
["Oncology","SAR442257 (anti CD38xCD28xCD3 trispecific mAb)","\nPhase 1\n","NCT04401020","First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL","• Neoplasm Malignant",57,"\n \n• Allocation: N/A\n• Intervention Model: Sequential Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: January 2024\nStudy Completion: April 2024"]
["Oncology","amcenestrant (SERD)","\nPhase 2\n","NCT04059484","Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer","• Breast Cancer Metastatic",372,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Single (Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: February 15, 2022\nStudy Completion: November 11, 2025"]
["Oncology","SAR444245 (Non-alpha IL-2)","\n• Phase 1\n• Phase 2\n","NCT04009681","A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors","• Metastasis",300,"\n \n• Allocation: Non-Randomized\n• Intervention Model: Sequential Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: April 2022\nStudy Completion: April 2022"]
["Oncology","SAR442720 (SHP2 inhibitor)","\n• Phase 1\n• Phase 2\n","NCT03989115","Dose-Escalation/Expansion of RMC-4630 and Cobimetinib in Relapsed/Refractory Solid Tumors and RMC-4630 and Osimertinib in EGFR Positive Locally Advanced/Metastatic NSCLC","• Solid Tumor",168,"\n \n• Allocation: Non-Randomized\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: March 31, 2022\nStudy Completion: April 30, 2022"]
["Oncology","SAR441000 (Cytokine mRNA)","\nPhase 1\n","NCT03871348","A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors","• Metastatic Neoplasm",231,"\n \n• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: June 2022\nStudy Completion: April 2024"]
["Oncology","SAR442720 (SHP2 inhibitor)","\nPhase 1\n","NCT03634982","Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors","• Solid Tumors",175,"\n \n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: October 1, 2021\nStudy Completion: October 1, 2021"]
["Oncology","tusamitamab ravtansine (anti-CEACAM5 ADC)","\nPhase 2\n","NCT05071053","Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab in\nPretreated Participants With Gastric Cancer","• Adenocarcinoma Gastric\n• Gastrooesophageal Cancer",38,"\n \n• Allocation: Non-Randomized\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: November 15, 2022\nStudy Completion: January 3, 2023"]
["Oncology","SAR444245 (Non-alpha IL-2)","\nPhase 2\n","NCT05061420","A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol)","• Squamous Cell Carcinoma of Head and Neck",160,"\n \n• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: December 22, 2023\nStudy Completion: December 22, 2023"]
["Oncology","SAR443216 (anti-CD3xCD28xHer2 trispecific mAb)","\nPhase 1\n","NCT05013554","Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/ Refractory HER2 Expressing Solid Tumors","• Neoplasm Malignant",184,"\n \n• Allocation: Non-Randomized\n• Intervention Model: Sequential Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: June 23, 2025\nStudy Completion: June 23, 2025"]
["Oncology","SAR444245 (Non-alpha IL-2)","\nPhase 2\n","NCT04914897","A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma","• Pleural Mesothelioma\n• Non-small Cell Lung Cancer",354,"\n \n• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: October 21, 2024\nStudy Completion: July 31, 2025"]
["Oncology","SAR444245 (Non-alpha IL-2)","\n• Phase 1\n• Phase 2\n","NCT04913220","A Study of SAR444245 Combined With Cemiplimab for the Treatment of\nParticipants With Various Advanced Skin Cancers","• Malignant Melanoma\n• Squamous Cell Carcinoma of Skin",80,"\n \n• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: June 23, 2023\nStudy Completion: July 23, 2024"]
["Oncology","SAR444881 (anti-ILT2 mAb)","\n• Phase 1\n• Phase 2\n","NCT04717375","Study of BND-22 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors","• Cancer",130,"\n \n• Allocation: Non-Randomized\n• Intervention Model: Sequential Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: September 2023\nStudy Completion: January 2024"]
["Oncology","tusamitamab ravtansine (anti-CEACAM5 ADC)","\nPhase 2\n","NCT04659603","SAR408701 in Patients With CEACAM5- positive Advanced Solid Tumors","• Breast Cancer Metastatic\n• Pancreatic Carcinoma Metastatic",64,"\n \n• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: January 2025\nStudy Completion: January 2025"]
["Oncology","SAR445710 (anti-PD-L1/IL-15 fusion protein)","\nPhase 1\n","NCT04242147","A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 in Subjects With Metastatic or Locally Advanced Solid Tumors.","• Advanced Solid Tumor",40,"\n \n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: November 2022\nStudy Completion: March 2023"]
["Oncology","SAR445419 (NK-cell-based immunotherapy)","\nPhase 1\n","NCT04220684","Off-the-shelf Third Party Expanded NK Cells in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome","• Allogeneic Stem Cell Transplant Recipient\n• Blasts 10 Percent or More of Bone Marrow Nucleated Cells\n• Myelodysplastic Syndrome\n• Recurrent Acute Myeloid Leukemia\n• Refractory Acute Myeloid Leukemia",44,"\n \n• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: December 31, 2021\nStudy Completion: December 31, 2021"]
["Oncology","Alomfilimab (SAR445256/Anti-ICOS mAb)","\n• Phase 1\n• Phase 2\n","NCT03829501","Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer","• Squamous Cell Carcinoma of Head and Neck\n• Non-small Cell Lung Cancer\n• Hepatocellular Carcinoma\n• Esophageal Cancer\n• Gastric Cancer\n• Melanoma\n• Renal Cell Carcinoma\n• Pancreatic Cancer\n• Cervical Cancer\n• Triple Negative Breast Cancer\n• Advanced Cancer\n• Metastatic Cancer",412,"\n \n• Allocation: Non-Randomized\n• Intervention Model: Sequential Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: May 2023\nStudy Completion: May 2023"]
["Oncology","SAR443579 (anti-NKp46/CD123 ","\n• Phase 1\n• Phase 2\n","NCT05086315","First-in-human Study of SAR443579 Infusion in Male and Female Participants of at Least 12 Years of Age With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL) or High Risk-myelodysplasia (HR- MDS)","• Acute Lymphocytic Leukaemia; Acute Myeloid Leukaemia Refractory; Myelodysplastic Syndrome",82,"\n \n• Allocation: Non-Randomized\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: October 9, 2026\nStudy Completion: January 7, 2032"]
["Oncology","SAR442720 (SHP2 inhibitor)","\nPhase 2\n","NCT05054725","Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies","• Non-Small Cell Lung Cancer",46,"\n \n• Allocation: Non-Randomized\n• Intervention Model: Sequential Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: March 31, 2023\nStudy Completion: January 19, 2024"]
["Oncology","SAR444245 (Non-alpha IL-2)","\nPhase 2\n","NCT05179603","A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol)","• Classic Hodgkin Lymphoma",25,"\n \n• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: March 22, 2026\nStudy Completion: April 27, 2026"]
["Neurology","tolebrutinub (BTK inhibitor)","\nPhase 3\n","NCT05132569","Efficacy and Safety of Tolebrutinib (SAR442168) Tablets in Adult Participants With Generalized Myasthenia Gravis","• Myasthenia Gravis",154,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Double (Participant, Investigator)\n• Primary Purpose: Treatment","Primary Completion: November 25, 2024\nStudy Completion: December 22, 2026"]
["Neurology","SAR441344 (anti-CD40L mAb)","\nPhase 2\n","NCT04879628","Proof-of-concept Study for SAR441344 in Relapsing Multiple Sclerosis","• Multiple Sclerosis",120,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: May 2022\nStudy Completion: December 2023"]
["Neurology","SAR445088 (Complement C1S inhibitor)","\nPhase 2\n","NCT04658472","Proof-of-concept Study for BIVV020 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","• Chronic Inflammatory Demyelinating Polyradiculoneuropathy",90,"\n \n• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: May 2024\nStudy Completion: May 2024"]
["Neurology","tolebrutinub (BTK inhibitor)","\nPhase 3\n","NCT04458051","Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168)","• Primary Progressive Multiple Sclerosis",990,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Triple (Participant, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: August 2024\nStudy Completion: August 2024"]
["Neurology","tolebrutinub (BTK inhibitor)","\nPhase 3\n","NCT04411641","Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168)","• Secondary Progressive Multiple Sclerosis",1290,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Triple (Participant, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: August 2024\nStudy Completion: August 2024"]
["Neurology","tolebrutinub (BTK inhibitor)","\nPhase 3\n","NCT04410991","Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168)","• Relapsing Multiple Sclerosis",900,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Triple (Participant, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: August 2023\nStudy Completion: August 2023"]
["Neurology","tolebrutinub (BTK inhibitor)","\nPhase 3\n","NCT04410978","Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168)","• Relapsing Multiple Sclerosis",900,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Triple (Participant, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: August 2023\nStudy Completion: August 2023"]
["Neurology","tolebrutinub (BTK inhibitor)","\nPhase 2\n","NCT03996291","Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis","• Relapsing Multiple Sclerosis",125,"\n \n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: April 2025\nStudy Completion: April 2025"]
["Rare diseases","venglustat (oral GCS inhibitor) ","\nPhase 3\n","NCT04221451","A Multinational, Randomized, Double- blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics,\nPharmacokinetics, and Safety of Venglustat in Late-onset GM2","• Tay-Sachs Disease Sandhoff Disease",77,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: January 9, 2024\nStudy Completion: January 9, 2024"]
["Rare diseases","Nexviazyme (Enzyme Replacement Therapy - GAA) ","\nPhase 2\n","NCT03019406","A Study to Assess Safety and Efficacy of Avalglucosidase Alfa Administered Every Other Week in Pediatric Patients With Infantile-onset Pompe Disease Previously Treated With Alglucosidase Alfa","• Glycogen Storage Disease Type II-Pompe's Disease",22,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: September 30, 2019\nStudy Completion: December 2024"]
["Rare diseases","SAR339375 (miR21 RNA) ","\nPhase 2\n","NCT02855268","Study of Lademirsen (SAR339375) in Patients With Alport Syndrome","• Alport's Syndrome",45,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Triple (Participant, Care Provider, Investigator)\n• Primary Purpose: Treatment","Primary Completion: December 4, 2023\nStudy Completion: December 4, 2023"]
["Rare diseases","venglustat (oral GCS inhibitor) ","\nPhase 2\n","NCT02843035","Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3","• Gaucher Disease Type 1\n• Gaucher Disease Type 3",13,"\n \n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: January 11, 2024\nStudy Completion: January 11, 2024"]
["Rare diseases","Nexviazyme (Enzyme Replacement Therapy - GAA) ","\nPhase 3\n","NCT02782741","Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease","• Glycogen Storage Disease Type II;Pompe's Disease",100,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: March 19, 2020\nStudy Completion: May 2023"]
["Rare diseases","Nexviazyme (Enzyme Replacement Therapy - GAA) ","\n• Phase 2\n• Phase 3\n","NCT02032524","Avalglucosidase Alfa Extension Study","• Glycogen Storage Disease Type II Pompe Disease",19,"\n \n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: March 18, 2022\nStudy Completion: March 18, 2022"]
["Rare diseases","olipudase alfa","\nPhase 2\n","NCT02004704","A Long-Term Study of Olipudase Alfa\nin Patients With Acid Sphingomyelinase Deficiency","• Sphingomyelin Lipidosis",25,"\n \n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: February 29, 2024\nStudy Completion: February 29, 2024"]
["Rare diseases","olipudase alfa","\n• Phase 2\n• Phase 3\n","NCT02004691","Efficacy, Safety, Pharmacodynamic, and Pharmacokinetics Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency","• Sphingomyelin Lipidosis",36,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: October 17, 2019\nStudy Completion: October 2023"]
["Rare blood disorders","SAR445088 (Complement C1S inhibitor)","\nPhase 1\n","NCT04802057","Safety and Tolerability Study in Adults With Cold Agglutinin Disease Previously Treated With BIVV020","• Autoimmune Haemolytic Anaemia",18,"\n \n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: May 2023\nStudy Completion: May 2023"]
["Rare blood disorders","rilzabrutinib (BTK inhibitor)","\nPhase 3\n","NCT04562766","Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)","• Immune Thrombocytopenia",224,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: October 2023\nStudy Completion: June 2025"]
["Rare blood disorders","SAR445088 (Complement C1S inhibitor)","\nPhase 1\n","NCT04269551","A Safety and Tolerability Study of BIVV020 in Adults With Cold Agglutinin Disease","• Autoimmune Haemolytic Anaemia",12,"\n \n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: December 10, 2021\nStudy Completion: December 10, 2021"]
["Rare blood disorders","efanesoctocog alfa (rFVIIIFc - vWF - XTEN)","\nPhase 3\n","NCT04161495","A Phase 3, Open-label Interventional Study of an Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand\nFactor-XTEN Fusion Protein, Efanesoctocog Alfa (BIVV001), in Patients With Severe Hemophilia A","• Factor VIII Deficiency",150,"\n \n• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: January 25, 2022\nStudy Completion: January 25, 2022"]
["Rare blood disorders","fitusiran (RNAi targeting anti-thrombin)  ","\n• Phase 2\n• Phase 3\n","NCT03974113","Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B","• Hemophilia",25,"\n \n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: August 9, 2023\nStudy Completion: December 2026"]
["Rare blood disorders","fitusiran (RNAi targeting anti-thrombin)  ","\nPhase 3\n","NCT03754790","Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX","• Hemophilia",244,"\n \n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: October 19, 2026\nStudy Completion: October 19, 2026"]
["Rare blood disorders","fitusiran (RNAi targeting anti-thrombin)  ","\nPhase 3\n","NCT03549871","A Study of Fitusiran in Severe Hemophilia A and B Patients Previously Receiving Factor or Bypassing Agent Prophylaxis","• Hemophilia",80,"\n \n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: March 18, 2022\nStudy Completion: September 14, 2022"]
["Rare blood disorders","rilzabrutinib (BTK inhibitor)","\n• Phase 1\n• Phase 2\n","NCT03395210","A Study of PRN1008 in Adult Patients With Immune Thrombocytopenia (ITP)","• Immune Thrombocytopenia\n• Immune Thrombocytopenic Purpura",85,"\n \n• Allocation: N/A\n• Intervention Model: Sequential Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: October 2022\nStudy Completion: September 2023"]
["Rare blood disorders","sutimlimab (anti-complement C1s mAb)","\nPhase 3\n","NCT03347422","A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Without A Recent History of Blood Transfusion","• Cold Agglutinin Disease",40,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Double (Participant, Investigator)\n• Primary Purpose: Treatment","Primary Completion: December 2021\nStudy Completion: December 2021"]
["Rare blood disorders","fitusiran (RNAi targeting anti-thrombin)  ","\n• Phase 1\n• Phase 2\n","NCT02554773","An Open-label Extension Study of an Investigational Drug, Fitusiran, in Patients With Moderate or Severe Hemophilia A or B","• Hemophilia A\n• Hemophilia B",37,"\n \n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: October 20, 2023\nStudy Completion: October 20, 2023"]
["Rare blood disorders","efanesoctocog alfa (rFVIIIFc - vWF - XTEN)","\nPhase 1\n","NCT04770935","To Assess the Pharmacokinetics and Safety and Tolerability of Efanesoctocog Alfa (BIVV001)in Adults With Type 2N and 3 Von Willebrand Disease (VWD)","• Von Willebrand's Disease (VWD)",9,"\n \n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Other","Primary Completion: May 7, 2022\nStudy Completion: May 25, 2022"]
["Rare blood disorders","efanesoctocog alfa (rFVIIIFc - vWF - XTEN)","\nPhase 3\n","NCT04759131","Safety, Efficacy and PK of BIVV001 in Pediatric Patients With Hemophilia A","• Hemophilia A",65,"\n \n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: February 2023\nStudy Completion: February 2023"]
["Rare blood disorders","Sarclisa (anti-CD38 mAb)","\n• Phase 1\n• Phase 2\n","NCT04661033","Safety, Pharmacokinetics, and Efficacy of Subcutaneous Isatuximab in Adults With Warm Autoimmune Hemolytic Anemia (wAIHA)","• Warm Autoimmune Hemolytic Anemia (wAIHA)",23,"\n \n• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: July 18, 2023\nStudy Completion: July 18, 2023"]
["Vaccines","Meninge Vaccine\nAfrica, Middle East","\nPhase 3\n","NCT04143061","Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, and Children in India and Healthy Adolescents and Children in the Republic of South Africa","• Healthy Volunteers (Meningococcal Infection)",1332,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: August 16, 2022\nStudy Completion: August 16, 2022"]
["Vaccines","Meninge Vaccine, North America","\nPhase 3\n","NCT04142242","Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine in Older Adults Who Received a Primary Vaccination (3 or More Years Earlier) in Study MET49","• Meningococcal Infection (Healthy Volunteers)",471,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Prevention","Primary Completion: April 1, 2020\nStudy Completion: April 2022"]
["Vaccines","Flu QIV HD Vaccine, Greater Europe","\nPhase 3\n","NCT04137887","Study to Evaluate the Effectiveness of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Adults 65 Years of Age and Older","• Influenza (Healthy Volunteers)",121000,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: August 31, 2024\nStudy Completion: August 31, 2024"]
["Vaccines","New Pertussis Vaccine, North America","\nPhase 1\n","NCT03958799","A Study to Describe the Safety Profile and Compare the Immune Response of 4\nDifferent Formulations of an Investigational Tdap Vaccine When Compared to Licensed Tdap Vaccine in Young Adults in Canada","• Tetanus Immunisation (Healthy Volunteers)\n• Diphtheria Immunisation (Healthy Volunteers)\n• Pertussis Immunisation (Healthy Volunteers)",71,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: April 6, 2021\nStudy Completion: April 6, 2021"]
["Vaccines","Meninge Vaccine\nAfrica, Middle-East","\nPhase 3\n","NCT03869866","Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) in Older Adults in Turkey and Lebanon","• Healthy Volunteers (Meningococcal Infection)",330,"\n \n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Prevention","Primary Completion: December 25, 2021\nStudy Completion: December 25, 2021"]
["Vaccines","Meninge Vaccine\nLatin America, North America","\nPhase 3\n","NCT03691610","Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","• Healthy Volunteers (Meningococcal Infection)",1070,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: May 2023\nStudy Completion: May 2023"]
["Vaccines","Meninge Vaccine, Asia Pacific, Greater Europe, Latin America","\nPhase 3\n","NCT03630705","Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico","• Healthy Volunteers (Meningococcal Infection)",525,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Prevention","Primary Completion: April 9, 2022\nStudy Completion: April 9, 2022"]
["Vaccines","Meninge Vaccine, Greater Europe","\nPhase 3\n","NCT03547271","Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe","• Meningococcal Infections",1540,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: November 2023\nStudy Completion: November 2023"]
["Vaccines","Meninge Vaccine, North America","\nPhase 3\n","NCT03537508","Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US","• Healthy Volunteers (Meningococcal Infection)",2628,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: September 28, 2023\nStudy Completion: September 28, 2023"]
["Vaccines","Dengue Vaccine, Asia Pacific, Latin America ","\n","NCT02948933","Cohort Event Monitoring for Dengvaxia®, CYD-TDV Dengue Vaccine","• Dengue Fever\n• Dengue Hemorrhagic Fever",30000,"\n \n• Observational Model: Cohort\n• Time Perspective: Prospective","Primary Completion: October 18, 2024\nStudy Completion: October 18, 2024"]
["Vaccines","Next Gen Flu, North America","\nPhase 1\n","NCT04451954","Study of Recombinant Influenza Vaccine Containing Different H3 Antigens Without or With Adjuvant in Healthy Adult Subjects","• Influenza",210,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: September 20, 2021\nStudy Completion: September 20, 2021"]
["Vaccines","Shanta Fully Liquid Hexavalent Vaccine, Asia Pacific","\nPhase 3\n","NCT04429295","Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand","• Pertussis Immunisation\n• Diphtheria Immunisation\n• Polio Immunisation\n• Hepatitis B Immunisation\n• Haemophilus Influenzae Type B Immunisation\n• Tetanus Immunisation\n• Rotavirus Immunisation\n• Pneumococcal Immunisation",460,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Prevention","Primary Completion: February 26, 2021\nStudy Completion: October 27, 2021"]
["Vaccines","Skypac, North America","\nPhase 2\n","NCT04398706","Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants","• Pneumococcal Immunisation\n• Diphtheria Immunisation\n• Tetanus Immunisation\n• Pertussis Immunisation\n• Hepatitis B Immunisation\n• Haemophilus Influenzae Type b Immunisation\n• Polio Immunisation\n• Measles Immunisation\n• Rubella Immunisation\n• Varicella Immunisation\n• Mumps Immunisation",840,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: July 6, 2023\nStudy Completion: July 6, 2023"]
["Vaccines","Adacel Quadra Vaccine, Africa, Middle East","\nPhase 4\n","NCT04300192","Study to Evaluate the Immune Response After Booster Vaccination With Tdap-IPV Vaccine (Against Tetanus, Diphtheria, Pertussis and Poliomyelitis) in Children Who Received Different Pertussis Primary Vaccine Regimens in Republic of South Africa","• Pertussis Immunisation\n• Diphtheria Immunisation\n• Tetanus Immunisation\n• Polyomyelitis Vaccine",350,"\n \n• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Prevention","Primary Completion: June 16, 2022\nStudy Completion: June 16, 2022"]
["Vaccines","HSV Vaccine, North America","\n• Phase 1\n• Phase 2\n","NCT04222985","Safety and Efficacy of 4 Investigational HSV 2 Vaccines in Adults With Recurrent Genital Herpes Caused by HSV 2","• Genital Herpes",381,"\n \n• Allocation: Randomized\n• Intervention Model: Sequential Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: May 2024\nStudy Completion: May 2024"]
["Vaccines","Flu QIV SHZ – CN, Asia Pacific","\nPhase 3\n","NCT04210349","Study of Shenzhen Quadrivalent Inactivated Influenza Vaccine Versus the Shenzhen Trivalent Inactivated Influenza Vaccine in Chinese Subjects From 6 Months of Age","• Influenza",7106,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Triple (Participant, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: December 1, 2020\nStudy Completion: December 1, 2020"]
["Vaccines","Next Gen Flu, North America","\nPhase 1\n","NCT04144179","Recombinant Influenza Vaccine Containing Different H3 Antigens in Healthy Adults 18 to 30 Years of Age","• Influenza",150,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Prevention","Primary Completion: February 24, 2020\nStudy Completion: February 24, 2020"]
["Vaccines","vYF Vaccine, North America","\n• Phase 1\n• Phase 2\n","NCT04142086","Dose-ranging Study of an Investigational Yellow Fever Candidate Vaccine in Adults","• Yellow Fever (Healthy Volunteers)",73,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: June 24, 2021\nStudy Completion: June 24, 2021"]
["Vaccines","Rabies Vaccine, Asia Pacific","\nPhase 3\n","NCT04127786","Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines, Given in a Pre-exposure Regimen in Pediatric and Adult Populations and as Single Booster Dose to a Subset of Adults","• Rabies (Healthy Volunteers)",1010,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: September 15, 2020\nStudy Completion: August 22, 2021"]
["Vaccines","Rabies Vaccine, Greater Europe","\nPhase 3\n","NCT03965962","Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines in a Simulated Post-Exposure Regimen in Adults","• Rabies (Healthy Volunteers)",640,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: December 22, 2020\nStudy Completion: July 1, 2021"]
["Vaccines","Meninge B, \nLatin America, Greater Europe, North America","\n• Phase 1\n• Phase 2\n","NCT04825223","Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants","• Meningococcal Immunisation",1800,"\n \n• Allocation: Randomized\n• Intervention Model: Sequential Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: July 23, 2025\nStudy Completion: July 23, 2025"]
["Vaccines","COVID-19 mRNA, \nLatin America,North America","\n• Phase 1\n• Phase 2\n","NCT04798027","Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older","• COVID-19",182,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: November 2, 2022\nStudy Completion: November 2, 2022"]
["Vaccines","COVID-19,\nLatin America,North America","\n• Phase 2\n• Phase 3\n","NCT04762680","Study of Recombinant Protein Vaccines With Adjuvant as a Primary Series and as a Booster Dose Against COVID-19 in Adults 18 Years of Age and Older","• COVID-19 (Healthy Volunteers)",5414,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: March 30, 2023\nStudy Completion: March 30, 2023"]
["Vaccines","Rabies Vaccine\nAsia Pacific","\nPhase 3\n","NCT04594551","Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post- Exposure Prophylaxis in Adults in Thaïland","• Rabies (Healthy Volunteers)",201,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: March 2, 2021\nStudy Completion: June 23, 2021"]
["Vaccines","Skypac\nNorth America","\nPhase 2\n","NCT04583618","Study of a Pneumococcal Conjugate Vaccine in Adults Aged 50 to 84 Years.","• Pneumoccocal Immunisation",750,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: August 9, 2021\nStudy Completion: January 8, 2022"]
["Vaccines","COVID-19, North America","\n• Phase 1\n• Phase 2\n","NCT04537208","Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older","• COVID-19 (Healthy Volunteers)",442,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: November 19, 2021\nStudy Completion: November 19, 2021"]
["Vaccines","Flu QIV HD Vaccine, Asia Pacific","\nPhase 3\n","NCT04498832","Study to Assess the Immuno Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD)\nCompared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older","• Influenza (Healthy Volunteers)",2100,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: January 14, 2021\nStudy Completion: January 14, 2021"]
["Vaccines","RSV Infant, Latin America","\n• Phase 1\n• Phase 2\n","NCT04491877","Study of a Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers","• Respiratory Syncytial Virus Infection",300,"\n \n• Allocation: Randomized\n• Intervention Model: Sequential Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: April 28, 2023\nStudy Completion: April 28, 2023"]
["Vaccines","Meninge Vaccine, Asia Pacific, Greater Europe","\nPhase 3\n","NCT04490018","Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to a Meningococcal Reference Vaccine, and When Given Alone or With Two Other Vaccines in Healthy Adolescents","• Meningococcal Infection (Healthy Volunteers)",464,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: February 12, 2022\nStudy Completion: February 12, 2022"]
["Vaccines","Rabies Vaccine, Asia Pacific","\nPhase 3\n","NCT04478084","Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post- Exposure Prophylaxis in Adult and Pediatric Population in Thaïland","• Rabies (Healthy Volunteers)",376,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: February 2022\nStudy Completion: August 6, 2022"]
["Vaccines","FLUBOK QIV","\nPhase 3\n","NCT05144945","Study Describing the Immunogenicity and Safety of Quadrivalent Recombinant\nInfluenza Vaccine (RIV4) Versus a Licensed Quadrivalent-inactivated Influenza Vaccine (IIV4) (Fluarix® Quadrivalent) in Participants 18 Years of Age and Older in South Korea","• Influenza (Healthy Volunteers)",300,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: July 2, 2022\nStudy Completion: July 2, 2022"]
["Vaccines","Flu seasonal Vaccine North America","\nPhase 2\n","NCT04969276","Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or\nSingly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine","• Influenza (Healthy Volunteers)",306,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Prevention","Primary Completion: February 2, 2022\nStudy Completion: February 2, 2022"]
["Vaccines","vYF Vaccine, North America","\nPhase 2\n","NCT04942210","Study on an Investigational Yellow Fever Vaccine Compared With YF-VAX in Adults in the USA","• Yellow Fever (Healthy Volunteers)",570,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: December 2, 2021\nStudy Completion: December 1, 2026"]
["Vaccines","Meninge Vaccine Greater Europe","\nPhase 3\n","NCT04936685","Study on an Investigational Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Administered as a Booster Dose in Children Vaccinated 5 Years Earlier as Toddlers","• Meningococcal Infection",250,"\n \n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Prevention","Primary Completion: December 27, 2022\nStudy Completion: December 27, 2022"]
["Vaccines","COVID-19, Greater Europe, Latin America, Asia Pacific, Africa and Middle-East, North America","\nPhase 3\n","NCT04904549","Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older","• COVID-19 (Healthy Volunteers)",21046,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: March 8, 2023\nStudy Completion: March 8, 2023"]